MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1164/rccm.201208-1352oc

Медицинская библиотека · American journal of respiratory and critical care medicine · 2012

Interferon-γ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial.

Adetifa Ifedayo M, Ota Martin O C, Jeffries David J, Lugos Moses D, Hammond Abdulrahman S, Battersby Nicholas J, Owiafe Patrick K, Donkor Simon D, Antonio Martin, Ibanga Hannah B, Brookes Roger H, Aka Peter, Walton Robert, Adegbola Richard A, Hill Philip C

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

RATIONALE: Biomarkers that can be used to evaluate new interventions against latent tuberculosis infection (LTBI) and predict reactivation TB disease are urgently required.

OBJECTIVES

To evaluate ESAT-6 and CFP-10 (EC) IFN-γ ELISPOT as a biomarker for treatment efficacy in LTBI.

METHODS

This was a randomized, blinded, and placebo-controlled trial of INH in EC ELISPOT and Mantoux test positive participants.

MEASUREMENTS AND MAIN

RESULTS

Participants received a 6-month course of 900 mg INH twice weekly or a matching placebo. INH acetylator genotypes were determined and urine tested for INH metabolites to confirm adherence. The proportion of positive responders for CFP-10 and ESAT-6 between treatment arms was compared using mixed effects logistic regression models. A Tweedie (compound Poisson) model was fitted to allow for zero inflation and overdispersion of quantitative response. The proportions of EC ELISPOT-positive subjects reduced over time (P < 0.001) but did not differ by study arm (P = 0.36). Median spot-forming units for ESAT-6 and CFP-10 also declined significantly with time (P < 0.001) but did not differ by study arm (P = 0.74 and 0.71, respectively). There was no evidence of an interaction between acetylator status and INH treatment with respect to ELISPOT results over time.

CONCLUSIONS

In contacts with LTBI, INH therapy plays no role in observed decreases in Mycobacterium tuberculosis antigen-specific T-cell responses over time. IFN-γ ELISPOT is probably not a useful biomarker of treatment efficacy in LTBI. Clinical trial registered with www.clinicaltrials.gov (NCT 00130325).

Для цитирования: Adetifa Ifedayo M, Ota Martin O C, Jeffries David J, Lugos Moses D, Hammond Abdulrahman S, Battersby Nicholas J, Owiafe Patrick K, Donkor Simon D, Antonio Martin, Ibanga Hannah B, Brookes Roger H, Aka Peter, Walton Robert, Adegbola Richard A, Hill Philip C. Interferon-γ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial.. American journal of respiratory and critical care medicine. 2012. DOI: 10.1164/rccm.201208-1352oc.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.